SSA
GTBP icon

Schonfeld Strategic Advisors’s GT Biopharma GTBP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-437
Closed -$23K – 2767
2022
Q3 		$23K Sell
437
-86
-16% -$6.58K ﹤0.01% 2707
2022
Q2 		$46K Buy
523
+20
+4% +$1.52K ﹤0.01% 2232
2022
Q1 		$43K Buy
+503
New +$44.4K ﹤0.01% 2355

Other funds holding GTBP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFS
Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schonfeld Strategic Advisors's GTBP Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of GT Biopharma (GTBP) in Q4 2022, closing a stake of 437 shares — an estimated $23K sold.

Schonfeld Strategic Advisors first reported a position in GTBP in Q1 2022 and held it in 3 quarters. The position peaked at $46K in Q2 2022. 36 funds tracked by Wall St. Rank hold GTBP as of Q4 2022.

  • Schonfeld Strategic Advisors reported no remaining GT Biopharma position as of Q4 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 437 GT Biopharma shares in Q4 2022, an estimated $23K.
  • Schonfeld Strategic Advisors first reported a position in GT Biopharma in Q1 2022 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's GT Biopharma position peaked at $46K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.